Lipids and lipoproteins in hyperlipidemia type IIa during treatment with different lipid lowering drugs.
In the present study we examined the effect of different lipid lowering drugs on lipids and lipoproteins in hyperlipoproteinemia type IIa. We have treated over 24 weeks 10 patients with 900 mg beta-pyridylcarbinol daily, 11 patients with 3 g of xantinolnicotinate, 4 patients with 600 mg bezafibrate daily and 10 patients with a combination of 2.4 g inositolnicotinate and 1.5 g clofibrate daily. One patient with familial hypercholesterolemia (untreated total cholesterol 800 mg%) received a combined drug treatment during 5 years. Total cholesterol decreased to 200 mg%, mainly due to decreases in LDL-cholesterol. However in HDL significant decreases of about 50% could be observed. Treatment with the four different drugs showed significant decrements in low density lipoproteins (LDL) whereas an increase of protective high density lipoproteins could not be observed.
D000293:Adolescent; D001629:Bezafibrate; D002994:Clofibrate / Q000627:therapeutic use; D002995:Clofibric Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000188:drug therapy*; D007294:Inositol / Q000031:analogs & derivatives / Q000627:therapeutic use; D008055:Lipids / Q000097:blood*; D008074:Lipoproteins / Q000097:blood*; D008075:Lipoproteins, HDL / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood; D008297:Male; D009539:Nicotinic Acids / Q000627:therapeutic use; D009540:Nicotinyl Alcohol / Q000627:therapeutic use; D014971:Xanthinol Niacinate / Q000627:therapeutic use
D008055:Lipids; D008074:Lipoproteins; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D009539:Nicotinic Acids; D007294:Inositol; D002995:Clofibric Acid; D014971:Xanthinol Niacinate; D009540:Nicotinyl Alcohol; C005193:Inositol Niacinate; D002994:Clofibrate; D001629:Bezafibrate